RxDoctor Payments DataLook up a doctor →

Joseph Grau, MD

Psychiatry · Bowling Green, KYNPI 1508868456

Payments from drug & device makers

$9,868in general payments, 2019–2025

Across 631 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$595
  • Sunovion Pharmaceuticals Inc.$553
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$9,67798%
  • Education$1912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,868 in reported general payments places this provider in the 90th percentile of 348 psychiatry providers in Kentucky.

See all psychiatry providers in Kentucky

Medicare billing

Part B allowed, 2024
$63,820
Medicare patients
257
Services billed
976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl16$18,788
TrintellixVortioxetine Hydrobromide23$14,612
Venlafaxine Hcl ErVenlafaxine Hcl165$5,464
Quetiapine Fumarate322$5,262
Trazodone Hcl476$4,023
Bupropion XlBupropion Hcl230$3,745
Olanzapine97$3,700
Aripiprazole58$3,653
Divalproex Sodium ErDivalproex Sodium88$3,449
Memantine Hcl ErMemantine Hcl27$3,264
Lurasidone Hcl23$3,043
Sertraline Hcl269$2,438
Duloxetine Hcl157$2,085
Buspirone Hcl226$1,900
Lamotrigine187$1,801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$2,680$18,78816 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$44$14,61223 claims
Almatica Pharma LLCSertraline Hcl$20$2,438269 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 348 psychiatry providers in Kentucky.

Other psychiatry in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →